HansGeorge Rammensee - Immatics Biotechnologies Head CoFounder
| IMTXW Stock | USD 0.50 0.10 25.00% |
Insider
HansGeorge Rammensee is Head CoFounder of immatics biotechnologies GmbH
| Address | Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 |
| Phone | 49 7071 5397 0 |
| Web | https://www.immatics.com |
Immatics Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.1217) % which means that it has lost $0.1217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2432) %, meaning that it generated substantial loss on money invested by shareholders. Immatics Biotechnologies' management efficiency ratios could be used to measure how well Immatics Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Immatics Biotechnologies' Other Current Assets are fairly stable compared to the past year. Asset Turnover is likely to climb to 0.14 in 2024, whereas Total Assets are likely to drop slightly above 325.9 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Patrick Amstutz | Molecular Partners AG | 49 | |
| , MBA | Molecular Partners AG | 51 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Dale Christensen | Tff Pharmaceuticals | N/A | |
| Quinn Deveraux | Inhibrx | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Harlan Weisman | Tff Pharmaceuticals | 72 | |
| James JD | Eliem Therapeutics | 58 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| BS CPA | Inhibrx | 42 | |
| Christopher Cano | Tff Pharmaceuticals | 53 | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 |
Immatics Biotechnologies Leadership Team
Elected by the shareholders, the Immatics Biotechnologies' board of directors comprises two types of representatives: Immatics Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immatics. The board's role is to monitor Immatics Biotechnologies' management team and ensure that shareholders' interests are well served. Immatics Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immatics Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrea Mokler, VP Sciences | ||
| Edward Sturchio, General Secretary | ||
| Arnd MBA, Chief Officer | ||
| Kristijan Lasic, Director Accounting | ||
| Miriam Meyer, VP Affairs | ||
| Toni Weinschenk, CoFounder Officer | ||
| Thomas Ulmer, Chief Officer | ||
| Jessica EdD, Director Operations | ||
| Evelyn RothGeissler, VP Operations | ||
| Carsten MD, Chief Officer | ||
| Steffen Walter, Chief Officer | ||
| Cedrik MD, Chief Officer | ||
| HansGeorg Rammensee, CoFounder Board | ||
| Dominik Maurer, Senior Unit | ||
| Edward JD, General Secretary | ||
| Harpreet Singh, Chief Officer | ||
| Ali Mohamed, Senior CMC | ||
| HansGeorge Rammensee, Head CoFounder | ||
| Emmanuelle MBA, VP Head | ||
| Ephraim MSc, Vice Accounting | ||
| Rainer Kramer, Chief Munich | ||
| Jordan Silverstein, Head Strategy |
Immatics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immatics Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.